Although it remains unclear how expression of CD36 on tumor-infiltrating T cells is regulated, this tissue selectivity provides a unique opportunity to develop promising strategies for metabolically targeting TME without significantly altering systemic tissue homeostasis. This evidence concerns the gene CD36 and neoplasm.